Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage biotechnology company developing targeted antitumor virotherapies, said Northwestern University/Northwestern Memorial Hospital is recruiting for its Phase 1B/2 clinical trial of “CLD-101” in newly diagnosed high-grade glioma patients. The company completed shipment of the first batch of CLD-101—comprising allogeneic neural stem cells loaded with the oncolytic adenovirus CRAd-S-pk7—to support the trial, which builds on promising Phase 1 results in 12 patients published in The Lancet Oncology. The physician-led and NCI-sponsored study, headed by Dr Maciej Lesniak and Dr Roger Stupp and funded by the NIH/NCI SPORE, aims to evaluate a multiple-dose regimen that could transform brain tumor treatment. Calidi CEO Allan Camaisa said the trial has the potential to pave the way for a broader portfolio addressing glioblastoma, solid tumors and metastatic cancer, while Dr Lesniak expressed excitement over the improved regimen initiated early in the disease.
To view the full press release, visit: https://ibn.fm/1oEwa
About Calidi Biotherapeutics
Calidi Biotherapeutics specializes in proprietary technology that empowers the immune system to combat cancer. The company’s novel stem cell-based platforms utilize potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in multiple oncology indications, including high-grade gliomas and solid tumors. Calidi’s clinical stage off-the-shelf, universal cell-based delivery platforms are designed to protect, amplify, and potentiate oncolytic viruses leading to enhanced efficacy and improved patient safety. Calidi’s preclinical off-the-shelf enveloped virotherapies are designed to target disseminated solid tumors. This dual approach can potentially treat, or even prevent, metastatic disease. Calidi Biotherapeutics is headquartered in San Diego, California. For more information, please visit www.calidibio.com.
NOTE TO INVESTORS: The latest news and updates relating to CLDI are available in the company’s newsroom at http://ibn.fm/CLDI
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com
BioMedWire is powered by IBN
